A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients with PDL-1 of 1%-49%

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pembrolizumab (Primary) ; Sargramostim (Primary) ; Carboplatin; Granulocyte macrophage colony stimulating factor; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use

01 Jan 2025 Status changed from recruiting to discontinued due to futility
21 Nov 2023 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
21 Nov 2023 Planned primary completion date changed from 1 May 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com